CTA
RXRX icon

Colonial Trust Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

Colonial Trust Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-200
Closed -$1.32K – 764
2024
Q3 		$1.32K Hold
200
– – ﹤0.01% 701
2024
Q2 		$1.5K Buy
+200
New +$1.74K ﹤0.01% 689

Other funds holding RXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Colonial Trust Advisors's RXRX Position: Q4 2024 in Review

Colonial Trust Advisors sold out of Recursion Pharmaceuticals (RXRX) in Q4 2024, closing a stake of 200 shares — an estimated $1.32K sold.

Colonial Trust Advisors first reported a position in RXRX in Q2 2024 and held it in 2 quarters. The position peaked at $1.5K in Q2 2024. 316 funds tracked by Wall St. Rank hold RXRX as of Q4 2024.

  • Colonial Trust Advisors reported no remaining Recursion Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Colonial Trust Advisors sold 200 Recursion Pharmaceuticals shares in Q4 2024, an estimated $1.32K.
  • Colonial Trust Advisors first reported a position in Recursion Pharmaceuticals in Q2 2024 and held it in 2 quarters.
  • Colonial Trust Advisors's Recursion Pharmaceuticals position peaked at $1.5K in Q2 2024.
  • 316 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2024.

Based on Colonial Trust Advisors's 13F filing for Q4 2024, filed 13 Feb 2025.